MoFo Advised Triastek on its Co-Development Agreement with Sperogenix Therapeutics

Morrison & Foerster advised Triastek, Inc., a leading pharmaceutical company specializing in 3D printing of drug products, on its co‑development agreement with Sperogenix Therapeutics Limited, a company focusing on development and commercialization of rare disease medications in China, to jointly develop 3D-printed medicines for rare diseases. The collaboration widens the application of 3D-printed medicines and advances the development of rare disease research.

The MoFo team was led by Shanghai TTG/M&A partner Chuan Sun and Palo Alto Patent partner Janet Xiao. Beijing associate Xuezi Dan also provided support to the project.

Triastek submitted pre-IND to USFDA in 2019 and entered the IND stage in 2020, making it one of the two companies in the world with a USFDA submission in drug 3D printing. In addition to the co-development agreement, the MoFo IP team has worked closely with Triastek to build a robust patent portfolio, which positions the company to be a dominating player in the drug 3D printing field.